Aldeyra Therapeutics (ALDX) Net Equity Issued and Repurchased (2013 - 2021)

Aldeyra Therapeutics' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $119.8 million for Q2 2021.

• Quarterly Net Equity Issued and Repurchased rose 868.1% year-over-year to $119.8 million in Q2 2021, while the trailing twelve-month figure through Mar 2022 was $119.8 million (down 12.9% YoY) and the FY2021 annual result came in at $189.8 million, up 366.18% from the prior year.
• Net Equity Issued and Repurchased was $119.8 million for Q2 2021 at Aldeyra Therapeutics, up from $100.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $119.8 million in Q2 2021 and bottomed at -$86643.0 in Q2 2019.
• A 5-year average of $22.8 million and a median of $7.2 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2018 — Net Equity Issued and Repurchased soared 1504932.73% — and 2019, when it plunged 100.96%.
• Aldeyra Therapeutics' Net Equity Issued and Repurchased stood at -$4495.0 in 2017, then surged by 1504932.73% to $67.6 million in 2018, then plunged by 89.4% to $7.2 million in 2019, then sank by 100.0% to $1.0 in 2020, then soared by 11979999900.0% to $119.8 million in 2021.
• Business Quant data shows ALDX's Net Equity Issued and Repurchased at $119.8 million in Q2 2021, $100.0 million in Q1 2021, and $1.0 in Q4 2020.